JUNB and idiopathic pulmonary fibrosis: The therapeutic benefits seen from using OSMI‐4 to block global O‐GlcNAc levels could extend beyond the effects on JUNB; the role of O‐GlcNAc‐modifications in the context of IPF is still largely unexplored and warrants further investigations.